Genomic Vision announced that its Molecular Combing technology will be used by the US National Institute of Standards and Technology (NIST) to characterize and quantify intended and unintended genome editing events in NIST's control material. The Molecular Combing technology is currently used for monitoring DNA replication in cancerous cell, for early cancer detection and the diagnosis of genetic diseases. Genomic Vision has been part of the NIST Genome Editing Consortium since March 2019. The consortium's goal is to address pre-competitive measurement needs which may eventually help to speed the process of bringing genome editing products to the market. The Consortium has 33 formal members and three working groups. Genomic Vision participates in the first working group, known as Specificity which aims to qualify the genomic assays used for evaluating genome editing outputs, and to design the control materials needed to increase confidence in genome editing.